Skip to main content

Table 4 Radiation equivalent doses in the tumour and liver in NRG mice with s.c. HNSCC primary xenografts for [177Lu]Lu-DOTA-panitumumab F(ab´)2 based on ROI analysis of biodistribution (BOD)

From: Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy

  Radiation equivalent dose a (Sv/MBq)
Organ 64Cu/PET b 64Cu/BOD c Comparison of doses for 177Lu estimated from 64Cu/PET b or 64Cu/BOD c
(P-value)
177Lu/BOD d Comparison of doses for 177Lu estimated from 64Cu/PET b or 177Lu/BOD d
(P-value)
Liver 1.45 ± 0.17 1.22 ± 0.13 n.s. 1.82 ± 0.14 n.s.
Tumour e 2.30 ± 0.40 2.00 ± 0.60 n.s. 2.50 ± 0.80 n.s.
  1. aThe equivalent doses (D) were calculated as D = Ãs × S × WR, where Ãs is the time-integrated activity in source organs and S are the Snyder values for 177Lu for mice (Bitar et al., 2007; Xie and Zaidi, 2013) and WR is the radiation weighing factor
  2. bThe time-integrated radioactivity was calculated based on microPET/CT studies of NRG mice injected i.v. (tail vein) with [64Cu]Cu-DOTA-panitumumab F(ab´)2
  3. cThe time-integrated radioactivity was calculated based on the BOD studies of NRG mice injected i.v. (tail vein) with [64Cu]Cu-DOTA-panitumumab F(ab´)2
  4. dThe time-integrated radioactivity was calculated based on the BOD studies of NRG mice injected i.v. (tail vein) with [177Lu]Lu-DOTA-panitumumab F(ab´)2
  5. eEstimated using the sphere model in OLINDA/EXM software based on the measured tumour mass (Stabin et al., 2005)